European Shorting
GLPGF has been successfully added into Your Stock Email Alerts list.
You can manage your stock email alerts here.
GLPGF has been removed from your Stock Email Alerts list.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash to Debt | No Debt |
GLPGF's Cash to Debt is ranked higher than
81% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 3.50 vs. GLPGF: No Debt ) |
GLPGF'
s 10-Year Cash to Debt Range
Min: No Debt Max: No Debt Current: No Debt |
| Equity to Asset | 0.503 |
GLPGF's Equity to Asset is ranked higher than
67% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 0.53 vs. GLPGF: 0.503 ) |
GLPGF'
s 10-Year Equity to Asset Range
Min: 0.5 Max: 0.77 Current: 0.5 |
| Interest Coverage | No Debt |
GLPGF's Interest Coverage is ranked higher than
99% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 0.00 vs. GLPGF: No Debt ) |
GLPGF'
s 10-Year Interest Coverage Range
Min: 2 Max: No Debt Current: No Debt |
| F-Score: 4 |
|
| Z-Score: 2.24 |
|
| M-Score: -1.89 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating margin (%) | -4.90 |
GLPGF's Operating margin (%) is ranked higher than
66% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: -4.90 vs. GLPGF: -4.90 ) |
GLPGF'
s 10-Year Operating margin (%) Range
Min: -59.2 Max: 1.8 Current: -4.9 |
| Net-margin (%) | -4.2 |
GLPGF's Net-margin (%) is ranked higher than
66% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: -4.20 vs. GLPGF: -4.2 ) |
GLPGF'
s 10-Year Net-margin (%) Range
Min: -58.2 Max: 3.6 Current: -4.2 |
| ROE (%) | -4.8 |
GLPGF's ROE (%) is ranked higher than
62% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 0.00 vs. GLPGF: -4.8 ) |
GLPGF'
s 10-Year ROE (%) Range
Min: -34.6 Max: 2.9 Current: -4.8 |
| ROA (%) | -2.4 |
GLPGF's ROA (%) is ranked higher than
66% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: -2.40 vs. GLPGF: -2.4 ) |
GLPGF'
s 10-Year ROA (%) Range
Min: -23 Max: 2.3 Current: -2.4 |
| Revenue Growth (%) | 5.8 |
GLPGF's Revenue Growth (%) is ranked higher than
87% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 0.00 vs. GLPGF: 5.8 ) |
GLPGF'
s 10-Year Revenue Growth (%) Range
Min: 0 Max: 30.3 Current: 5.8 |
| EBITDA Growth (%) | -30.2 |
GLPGF's EBITDA Growth (%) is ranked lower than
58% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 0.00 vs. GLPGF: -30.2 ) |
GLPGF'
s 10-Year EBITDA Growth (%) Range
Min: -30.2 Max: 20.9 Current: -30.2 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| P/B | 3.40 |
GLPGF's P/B is ranked higher than
69% of the 606 Companies in the Global Biotechnology industry. ( Industry Median: 3.56 vs. GLPGF: 3.40 ) |
GLPGF'
s 10-Year P/B Range
Min: 0.59 Max: 4.48 Current: 3.4 |
| P/S | 3.00 |
GLPGF's P/S is ranked higher than
84% of the 677 Companies in the Global Biotechnology industry. ( Industry Median: 7.38 vs. GLPGF: 3.00 ) |
GLPGF'
s 10-Year P/S Range
Min: 0.9 Max: 5.62 Current: 3 |
| PFCF | 7.10 |
GLPGF's PFCF is ranked higher than
91% of the 244 Companies in the Global Biotechnology industry. ( Industry Median: 27.82 vs. GLPGF: 7.10 ) |
GLPGF'
s 10-Year PFCF Range
Min: 7.1 Max: 240 Current: 7.1 |
| EV-to-EBIT | 18.9 |
GLPGF's EV-to-EBIT is ranked lower than
77% of the 244 Companies in the Global Biotechnology industry. ( Industry Median: 22.58 vs. GLPGF: 18.9 ) |
GLPGF'
s 10-Year EV-to-EBIT Range
Min: 43.4 Max: 135.9 Current: 18.9 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price/Tangible Book | 5.7 |
GLPGF's Price/Tangible Book is ranked higher than
65% of the 564 Companies in the Global Biotechnology industry. ( Industry Median: 5.60 vs. GLPGF: 5.7 ) |
GLPGF'
s 10-Year Price/Tangible Book Range
Min: 1.5 Max: 5.9 Current: 5.7 |
| Price/DCF (Projected) | 4.4 | ||
| Price/Median PS Value | 1 |
GLPGF's Price/Median PS Value is ranked higher than
68% of the 550 Companies in the Global Biotechnology industry. ( Industry Median: 1.00 vs. GLPGF: 1 ) |
GLPGF'
s 10-Year Price/Median PS Value Range
Min: 0.3 Max: 1.6 Current: 1 |
| Forward Rate of Return (Yacktman) | -0.07 |
GLPGF's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 834 Companies in the Global Biotechnology industry. ( Industry Median: 0.00 vs. GLPGF: -0.07 ) |
GLPGF'
s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.3 Max: -4.1 Current: -0.07 |
| Industry: | Biotechnology | |
|---|---|---|
| Compare: | NVO, AMGN, GILD, LSE:0Q4U, BIIB | |
| Traded in other countries: | GLPG.Belgium, GXE.Germany |
Feedback
My Portfolios
Browse Gurus
Bookmark
Add to Portfolio
Get Email Alerts
RSS Update
Company Website
SEC Reports
RSS